Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring

The document discussed two cases of alopecia areata treated with ruxolitinib, a JAK1/JAK2 inhibitor. Both patients, one with chronic alopecia areata and the other with acute onset alopecia universalis, experienced near-complete hair regrowth after one year of treatment without significant complications. The study suggested that ruxolitinib could be a viable long-term treatment option for alopecia, especially in cases unresponsive to other therapies. The treatment was well-tolerated, with only minor hematologic changes and some side effects like weight gain and bloating. The findings supported the need for maintaining an appropriate dose to sustain hair growth and highlighted the importance of regular monitoring.